{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-22-000067","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.115500+00:00","generated_at":"2026-06-25T21:38:51.489534+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sera Prognostics Q1 net loss $12.2M; revenue $38k; PreTRM orders rise","bullets":["Revenue of $38k in Q1 2022 vs $13k in Q1 2021; still minimal.","Net loss widened to $12.2M from $6.4M; operating expenses $12.3M vs $6.0M.","Cash and securities total $129.9M as of March 31, 2022.","Simplified PreTRM ordering process; order trends improving into Q2.","Preeclampsia biomarker validation expected mid-2022; PRIME study on track for 2023 interim readout."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-22-000067","json":"https://secwatch.observer/filing/0001534969-22-000067.json","markdown":"https://secwatch.observer/filing/0001534969-22-000067.md","text":"https://secwatch.observer/filing/0001534969-22-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000067/0001534969-22-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496922000067/sera-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:38:51.489534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}